Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR2 | P21802 | 1/20 | 0.44 |
| ▸ | FLT3 | P36888 | 6/20 | 0.43 |
| ▸ | KDR | P35968 | 3/20 | 0.43 |
| ▸ | AXL | P30530 | 4/20 | 0.42 |
| ▸ | SRC | P12931 | 3/20 | 0.42 |
| ▸ | TGFBR1 | P36897 | 3/20 | 0.42 |
| ▸ | PDGFRA | P16234 | 3/20 | 0.42 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30465792 | 0.96 | FLT3 (0.46) | FGFR2FLT3KDRAXLSRC | |
| SCHEMBL25285080 | 0.89 | FGFR2 (0.42) | FGFR2FLT3KDRAXLPDGFRA | |
| SCHEMBL30465770 | 0.86 | AXL (0.42) | FGFR2FLT3KDRAXLSRC | |
| SCHEMBL30465769 | 0.84 | FGFR2 (0.43) | FGFR2FLT3KDRAXLPDGFRA | |
| SCHEMBL25239146 | 0.84 | FLT3 (0.49) | FGFR2FLT3AXLSRCTGFBR1 | |
| SCHEMBL30465700 | 0.81 | FLT3 (0.44) | FGFR2FLT3KDRAXLSRC | |
| SCHEMBL25719085 | 0.81 | AXL (0.49) | FGFR2KDRAXLPDGFRAPDGFRB | |
| SCHEMBL30465793 | 0.81 | EGFR (0.44) | FGFR2FLT3KDRAXLPDGFRA | |
| SCHEMBL25261932 | 0.80 | PDGFRA (0.47) | FGFR2FLT3KDRAXLPDGFRA | |
| SCHEMBL30565662 | 0.80 | PDGFRA (0.47) | FGFR2FLT3KDRAXLPDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4448510-A1 | INHIBITORS OF MET KINASE | Kinnate Biopharma Inc. (US) | 2024-10-23 | — | — | EP | disclosed |
| WO-2023114809-A1 | INHIBITORS OF MET KINASE | KINNATE BIOPHARMA INC. (US) | 2023-06-22 | — | — | WO | disclosed |